索拉非尼或安慰剂治疗放射性碘难治性晚期分化型甲状腺癌患者的人体成分:III期DECISION试验的回顾性分析
该研究为III期DECISION试验的回顾性探索性分析,纳入365例有CT扫描可评估肌肉量的放射性碘难治性晚期分化型甲状腺癌患者,比较索拉非尼组(180例)与安慰剂组(185例)的人体成分变化及肌少症与早期剂量调整的关系。结果显示索拉非尼显著降低体重、体质指数和瘦体重,但肌少症与剂量调整或早期剂量调整无关联。
要点
- 索拉非尼组6个月时平均体重、体质指数和瘦体重均低于基线,且显著低于安慰剂组(均p<0.0001)。
- 肌少症患者早期剂量调整比例55.3% vs 无肌少症者44.7%,差异无统计学意义(p=0.2273)。
- 索拉非尼组中约半数患者存在肌少症风险(89/180;49.4%),地理分布差异大。
核心结论
- 索拉非尼对肌肉量有显著影响,但肌少症与剂量调整或早期剂量调整无关联,与肝细胞癌和肾细胞癌中的观察相反。
研究设计与样本
- III期DECISION试验的回顾性探索性分析,纳入365例有CT扫描可评估肌肉量的放射性碘难治性晚期分化型甲状腺癌患者,索拉非尼组180例,安慰剂组185例。
主要发现
- 索拉非尼组6个月时平均体重、体质指数和瘦体重低于基线,且显著低于安慰剂组(均p<0.0001)。
- 肌少症患者早期剂量调整比例为55.3%,无肌少症者为44.7%,差异无统计学意义(p=0.2273)。
- 大多数剂量调整和严重毒事件发生在治疗第一个月内。
- 索拉非尼组中约半数患者存在肌少症风险(89/180;49.4%),地理分布差异大。
关键数值与推荐
- 肌少症定义为骨骼肌指数低于性别特异性骨骼肌指数中位数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Rates of adverse events with sorafenib were higher in the DECISION trial in radioactive iodine-refractory, advanced differentiated thyroid cancer (DTC) than in trials of sorafenib for other tumor types. One possible explanation is that sarcopenia, a known predictive factor of toxicity in patients with cancer, is more common in patients with DTC due to hormone suppressive therapy. Methods: This retrospective exploratory analysis was performed to assess whether the risk of early toxicity leading to dose modification (DMT) with sorafenib was higher in patients with sarcopenia compared with those without sarcopenia. The data set comprised patients from the phase III DECISION trial with a computed tomography scan available to determine muscle mass. The skeletal muscle (SM) cross-sectional area was used to determine the SM index and define sarcopenia. The end points were changes in body composition, DMT, early DMT (within 1 month), severe toxic events (STEs), and early STEs. Results: Overall, 365 patients were eligible for this analysis; baseline characteristics were well balanced between patients receiving sorafenib (n = 180) versus placebo (n = 185). Using a sarcopenia definition of an SM index less than the median sex-specific SM index, approximately half of the patients receiving sorafenib were at risk of sarcopenia (89/180; 49.4%), with wide geographical variation. At 6 months, the mean weight, body mass index, and lean body mass of patients receiving sorafenib were lower than at baseline and significantly lower than for patients receiving placebo (all p < 0.0001). Most DMTs and STEs occurred in the first month of treatment. There was a nonsignificant trend for more early DMTs in patients with sarcopenia compared with those without sarcopenia (55.3% vs. 44.7%, respectively; p = 0.2273). Conclusions: These results show a significant effect of sorafenib on muscle mass. However, there was no association between sarcopenia and DMT or early DMT, in contrast to observations in hepatocellular and renal cell carcinoma.
引用
- Huillard O, Jouinot A, Tlemsani C, et al. Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial. Thyroid. 2019. PMID: 31860408. doi:10.1089/thy.2018.0784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。